High-dose destyrosine-γ-endorphin in tardive dyskinesia

Søren Korsgaard, Daniel E. Casey, Jes Gerlach

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Destyrosine-γ-endorphin (DTGE) has purported neuroleptic properties, although the findings have been conflicting. Four chronic psychotic inpatients with neuroleptic-induced dyskinesias were treated with single injections of placebo and DTGE in high doses (20-120 mg). No consistent differences were found in tardive dyskinesia, parkinsonism, eye-blindking rates, or mental status. Laboratory tests were unchanged. It is concluded that acute DTGE treatment has no beneficial effect in drug-induced dyskinesia.

Original languageEnglish (US)
Pages (from-to)285-286
Number of pages2
Issue number3
StatePublished - Nov 1982
Externally publishedYes


  • Antipsychotic effect
  • Destyrosine-γ-endorphin
  • Eye-blinking rates
  • Parkinsonism
  • Tardive dyskinesia
  • dopaminergic activity

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'High-dose destyrosine-γ-endorphin in tardive dyskinesia'. Together they form a unique fingerprint.

Cite this